NCT05369130 Investigate and Predict Aortic & Thoracic Surgery Persistenet Postsurgical Pain
| NCT ID | NCT05369130 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Queen Mary University of London |
| Condition | Persistent Postsurgical Pain |
| Study Type | OBSERVATIONAL |
| Enrollment | 60 participants |
| Start Date | 2022-06-12 |
| Primary Completion | 2029-01-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 60 participants in total. It began in 2022-06-12 with a primary completion date of 2029-01-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is an observational clinical study aiming to further the wider understanding of patients who develop persistent pain after Thoracoabdominal Aorta surgery, a surgical cohort who are disproportionately affected. This will be undertaken through a prospective biopsychosocial characterisation of the phenotype of patients undergoing this operation. Increasing numbers of patients are undergoing surgery on the chest for treatment of heart or lung cancer disease. Over the last twenty years, the medical community has become increasingly aware of the long-term effect of this surgery in producing persistent pain, approximately half of all survivors are still in pain around their surgical incision at three months postoperatively and beyond. There is currently no accepted method for preventing this phenomenon. The nervous system mechanisms for the development of persistent pain after surgery are unclear. Some studies suggest it may involve the patient's ability to dampen down pain signals travelling from the incision site to the brain. Humans have an in-built system that produces opiates as well as other pain-relieving molecules in response to injury, e.g. surgery. However, this response varies hugely from person to person and may even be impacted by the psychological state of the individual at the time of surgery. Some of these pain modulating mechanisms can be measured before and after surgery in patients using sensory testing, a robust and established objective method to assess patients'. Identifying patients who are most at risk of a persistent pain state will allow both academics and clinicians to investigate and better target appropriate treatments. Undertaking these longitudinal observational assessments will facilitate an improved mechanistic insight of the transition from acute to pathological pain, with the ultimate goal of improving outcomes for patients'.
Eligibility Criteria
Inclusion Criteria: * Adults (over 18 years of age) undergoing elective repair of the thoraco-abdominal aorta. Able to adequately understand and respond to verbal instructions Exclusion Criteria: * Unwilling or unable to give consent, Age \<18 years
Contact & Investigator
Sibtain Anwar, MBBS MA PhD
STUDY CHAIR
Barts Health NHS Trust & Queen Mary University of London
Frequently Asked Questions
Who can join the NCT05369130 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Persistent Postsurgical Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05369130 currently recruiting?
Yes, NCT05369130 is actively recruiting participants. Contact the research team at b.herath@nhs.net for enrollment information.
Where is the NCT05369130 trial being conducted?
This trial is being conducted at London, United Kingdom.
Who is sponsoring the NCT05369130 clinical trial?
NCT05369130 is sponsored by Queen Mary University of London. The principal investigator is Sibtain Anwar, MBBS MA PhD at Barts Health NHS Trust & Queen Mary University of London. The trial plans to enroll 60 participants.